{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:06:31Z","timestamp":1792033591135,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Pathology Department of Massachusetts General Hospital"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.humpath.2018.11.022","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T12:29:34Z","timestamp":1545913774000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms"],"prefix":"10.1016","volume":"86","author":[{"given":"Leonardo","family":"Boiocchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Hasserjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Pozdnyakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waihay J.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen K.","family":"Lennerz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long Phi","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Dias-Santagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Iafrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela S.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2018.11.022_bb0005","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.11.022_bb0010","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2018.11.022_bb0015","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2018.11.022_bb0020","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.11.022_bb0025","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/leu.2013.302","article-title":"Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms","volume":"28","author":"Tenedini","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2018.11.022_bb0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2018.11.022_bb0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2018.11.022_bb0040","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.14269","article-title":"Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera","volume":"175","author":"Delic","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2018.11.022_bb0045","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2018.11.022_bb0050","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00277-017-3193-5","article-title":"Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up","volume":"97","author":"Senin","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.humpath.2018.11.022_bb0055","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2018.11.022_bb0060","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2018.11.022_bb0065","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/leu.2011.320","article-title":"SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients","volume":"26","author":"Lasho","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2018.11.022_bb0070","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/leu.2011.232","article-title":"SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts","volume":"26","author":"Visconte","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2018.11.022_bb0075","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ajh.24637","article-title":"Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2018.11.022_bb0080","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/leu.2013.120","article-title":"Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"27","author":"Broseus","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2018.11.022_bb0085","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s12185-017-2242-0","article-title":"Splicing factor mutations in MDS RARS and MDS\/MPN-RS-T","volume":"105","author":"Yoshimi","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.humpath.2018.11.022_bb0090","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"93","article-title":"Myelodysplastic\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis","author":"Orazi","year":"2017"},{"key":"10.1016\/j.humpath.2018.11.022_bb0095","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.11.022_bb0100","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.11.022_bb0105","series-title":"Myelodysplastic syndrome with ring sideroblasts. WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"109","author":"Hasserjian","year":"2017"},{"key":"10.1016\/j.humpath.2018.11.022_bb0110","series-title":"Myeloproliferative neoplasms. WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"29","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.humpath.2018.11.022_bb0115","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2018.11.022_bb0120","series-title":"ISCN (2009): an international system for human cytogenetic nomenclature","year":"2009"},{"key":"10.1016\/j.humpath.2018.11.022_bb0125","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jmoldx.2016.02.003","article-title":"Validation and Implementation of a custom next-generation sequencing clinical assay for hematologic malignancies","volume":"18","author":"Kluk","year":"2016","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2018.11.022_bb0130","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.3324\/haematol.2017.178988","article-title":"JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"103","author":"Wong","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2018.11.022_bb0135","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2009-10-201848","article-title":"Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies","volume":"115","author":"O'Keefe","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2018.11.022_bb0140","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2012-05-430876","article-title":"SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes","volume":"120","author":"Visconte","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2018.11.022_bb0145","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.mayocp.2017.06.002","article-title":"Genetic risk assessment in myeloproliferative neoplasms","volume":"92","author":"Tefferi","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.humpath.2018.11.022_bb0150","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.24973","article-title":"Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms","volume":"93","author":"Venton","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2018.11.022_bb0155","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/modpathol.2013.109","article-title":"Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage","volume":"26","author":"Boiocchi","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2018.11.022_bb0160","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.24978","article-title":"Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2018.11.022_bb0165","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/gcc.21960","article-title":"Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms","volume":"51","author":"Brecqueville","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.humpath.2018.11.022_bb0170","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kroger","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2018.11.022_bb0175","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718304763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718304763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:35:05Z","timestamp":1758645305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817718304763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":35,"alternative-id":["S0046817718304763"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2018.11.022","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2018.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}